Cassava Sciences, Inc.

NasdaqCM:SAVA 株式レポート

時価総額:US$1.4b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Cassava Sciences マネジメント

マネジメント 基準チェック /34

Cassava Sciences'の CEO はRick Barryで、 Sep2024年に任命され、 の在任期間は 3.25年です。 は、会社の株式の0.98%を直接所有しており、その価値は$ 12.68M 。経営陣と取締役会の平均在任期間はそれぞれ1.9年と9.9年です。

主要情報

Rick Barry

最高経営責任者

US$546.2k

報酬総額

CEO給与比率n/a
CEO在任期間no data
CEOの所有権1.0%
経営陣の平均在職期間2.8yrs
取締役会の平均在任期間9.9yrs

経営陣の近況

Recent updates

Cassava Sciences: Turning The Corner Into A Brick Wall

Jul 24

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Oct 17
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Jul 04
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Mar 05
We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Nov 19
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Oct 13

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Sep 29

Cassava Sciences: Trying To Manage Expectations

Sep 21

Cassava Sciences reaches over five-month high on rising volumes

Sep 09

Cassava Sciences Looks As Good Of A Purchase As Ever

Sep 03

Cassava Sciences stock jumps 10% after director buys $860K shares

Aug 26

Cassava Sciences rally continues as stock up 39%

Aug 17

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Aug 11

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

Aug 03

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Jul 27

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Jun 10

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

May 31

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

Apr 19
Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences

Apr 07

Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences

Mar 31

Cassava Sciences: Why The Stock Is Rangebound

Feb 28

The FDA Deals Another Blow To Cassava Sciences' Bears

Feb 11

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

Feb 02

INmune Bio, The Biotech In My Stable For After Cassava Sciences

Jan 17

Cassava Sciences, Inc. - The Short Squeeze Has Started

Jan 06

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

Dec 30

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Dec 28
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Cassava Sciences Stock: Here We Go Again

Dec 21

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

Dec 02

Cassava Sciences Gets Underway Putting Simufilam To The Test

Nov 24

Cassava Sciences: Data Rules!

Nov 17

Cassava Sciences' Hypothesis Raises Doubts

Nov 08

CEO(最高経営責任者

Rick Barry (65 yo)

no data

在職期間

US$546,155

報酬

Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Richard Barry
CEO & Directorno dataUS$546.16k0.98%
$ 13.4m
Eric Schoen
Chief Financial Officer5.9yrsUS$2.99m0.049%
$ 663.8k
R. Cook
Senior VP1.9yrsUS$1.27m0%
$ 0
James Kupiec
Chief Medical Officer3.7yrsUS$2.97m0.0083%
$ 114.0k
George Thornton
Senior Vice President of Technologyno dataデータなしデータなし
Michael Zamloot
Senior Vice President of Technical Operationsno dataデータなしデータなし
Michael Marsman
Senior Vice President of Regulatory Affairs1.8yrsデータなしデータなし
Lindsay Burns
Senior Vice President of Neuroscience4.4yrsデータなしデータなし

2.8yrs

平均在職期間

62.5yo

平均年齢

経験豊富な経営陣: SAVAの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Richard Barry
CEO & Director3.3yrsUS$546.16k0.98%
$ 13.4m
Sanford Robertson
Lead Independent Director26yrsUS$546.16k2.37%
$ 32.4m
Patrick Scannon
Independent Director16.8yrsUS$438.42k0.0025%
$ 34.2k
Michael O'Donnell
Independent Director26.3yrsUS$438.42k0.017%
$ 234.9k
Grant Schoenhard
Member of Scientific Advisory Board9.9yrsUS$558.31kデータなし
Robert Gussin
Independent Director21.5yrsUS$546.16k0.027%
$ 362.8k
Claude Nicaise
Independent Chairmanless than a yearUS$474.50k0%
$ 0
Robert Anderson
Independent Directorless than a yearUS$474.50k0%
$ 0
Pierre Gravier
Independent Directorless than a yearUS$474.50k0%
$ 0

9.9yrs

平均在職期間

71yo

平均年齢

経験豊富なボード: SAVAの 取締役会経験豊富 であると考えられます ( 9.8年の平均在任期間)。